Weekly Research Digest

Oncology AI Weekly

2026-05-26  ·  30 papers reviewed

Editor's Note

This week's most consequential theme is the maturation of immune-redirection strategies across cancer types — from the first approved ImmTAC biologic in uveal melanoma to bispecific antibodies, CAR T-cell MRD-guided intervention, and dual checkpoint blockade in MSI-H tumours. Tebentafusp's phase III survival benefit in a historically intractable disease validates the TCR-based platform and opens a new chapter in intracellular antigen targeting. Simultaneously, an expanding portfolio of MRD-guided and biomarker-selected trials signals that oncology is moving decisively from tumour-histology-driven to molecular-state-driven treatment decisions. Clinicians should watch this convergence closely — the tools to act on these signals are arriving rapidly.

AI in Oncology

AI applications this week span a broad methodological spectrum — from causal inference frameworks to single-cell-integrated prognostic signatures — but are uniformly limited by the absence of prospective validation or clinical deployment data. The most technically ambitious work is the mitoxyperilysis-based melanoma prognostic model (Paper 4), which benchmarks 101 ML strategies against TCGA-SKCM data and validates a gradient boosting machine signature across six GEO cohorts; the identification of GPR143 as a functionally relevant candidate gene adds biological depth. The CLL survival pipeline (Paper 2) is notable for its emphasis on individual-level uncertainty quantification and treatment-era sensitivity — both critical for real-world clinical trust — but the abstract omits algorithm type, cohort size, and performance metrics, limiting appraisal. The Atlantic PATH causal inference study (Paper 3) merits attention for distinguishing association from causal effect estimation using X-Learner, though findings (age, arthritis, hypertension) are modest and hypothesis-generating. The RESILIENCE-e frailty index study (Paper 5) and IRONMAN registry (Paper 1) represent infrastructure investments whose AI utility will depend on future analyses. The HPV single-dose trial (Paper 6) has been grouped here but contains no AI component; it would be better classified under Clinical Trials or Novel Treatments.

CLINICALTRIALS  ·  2017-05-12  ·  Significance: 2/5

The IRONMAN (International Registry to Improve Outcomes in Men with Advanced Prostate Cancer) registry is a prospective, international cohort study aiming to enrol a minimum of 5,000 men with advanced prostate cancer, specifically metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic or metastatic castration-resistant prostate cancer (M0/M1 CRPC). Recruiting across 15+ countries spanning multiple continents, the registry collects detailed clinical data, patient-reported outcome measures (PROMs) every three months, physician questionnaires at key treatment milestones, and serial blood samples (plasma, cell-free DNA, buffy coat/RNA) for biomarker discovery. Minimum follow-up is five years, with overall survival as a primary endpoint. The study aims to characterise treatment variation across academic and community settings globally, identify optimal treatment sequences, and validate molecular predictors of therapeutic response and resistance. Note: this is a registry protocol entry, not a results publication; no efficacy or outcome data are available from this abstract.

Key Findings

PUBMED  ·  2026-05-21  ·  Significance: 2/5

A machine learning pipeline was developed and validated on a large-scale, real-world cohort to predict overall survival (OS) in patients with Chronic Lymphocytic Leukemia (CLL). The model was designed to capture survival differences across treatment eras and incorporated individual-level uncertainty quantification, which showed good alignment with observed outcomes. The authors highlight the potential of this approach to support personalized risk stratification in CLL. Note: the abstract is brief and does not detail the specific ML algorithm used, cohort size, performance metrics, or the clinical variables included as model inputs, limiting full appraisal of the methodology.

Key Findings

PUBMED  ·  2026-05-21  ·  Significance: 2/5

This study uses machine learning and causal inference methods to identify health features associated with prevalent cancer and causally linked to incident cancer in males. Using longitudinal data from 6,409 male participants in the Atlantic PATH cohort, the authors applied univariate/bivariate analyses for prevalent cancer associations and an X-Learner causal inference algorithm (with Gradient Boosting, LightGBM, and Random Forest models) to estimate Average Treatment Effects for incident cancer. Changes in 12 binary, 2 continuous, and 2 categorical features were associated with prevalent cancer. Among significant predictors for incident cancer, changes in age, arthritis, and hypertension showed modest but consistent causal effects. The authors appropriately caution that findings are conditional on observational data and modelling assumptions.

Key Findings

PUBMED  ·  2026-01-01  ·  Significance: 2/5

This study develops a machine-learning-based prognostic framework for melanoma centred on "mitoxyperilysis" — a proposed mitochondria-dependent membrane lysis process. Using single-cell RNA-seq data, the authors derived a mitoxyperilysis-related score (MRS) to characterise tumour heterogeneity and cell-cell communication differences between MRS-high and MRS-low states. The top 150 MRS-correlated genes were then used to benchmark 101 machine-learning strategies in TCGA-SKCM, with external validation across six independent GEO cohorts. A gradient boosting machine (GBM)-derived risk signature most consistently stratified overall survival. High-risk tumours were associated with an immune-cold microenvironment, higher tumour purity, and reduced immune/stromal signals. The candidate gene GPR143 was upregulated in melanoma and associated with worse survival; functional knockdown suppressed colony formation in vitro. The abstract is complete, though the clinical utility of the risk score requires prospective validation.

Key Findings

CLINICALTRIALS  ·  2025-09-16  ·  Significance: 2/5

This is a prospective single-arm interventional study (RESILIENCE-e) recruiting adults aged 65 or older with active cancer who are classified as pre-frail or frail using an EHR-based Electronic Frailty Index (eFI) and are planned to receive outpatient chemotherapy. Following a baseline frailty assessment, participants receive personalised frailty result feedback, referrals for supportive care interventions, and engage in weekly symptom reporting. The primary goal is to better understand the needs of older adults undergoing chemotherapy and to tailor care pathways accordingly. The abstract is incomplete — specific endpoints, sample size, and outcome measures are not fully described in the available text. This is an early-stage clinical study currently recruiting; no results are available.

Key Findings

CLINICALTRIALS  ·  2022-02-14  ·  Significance: 3/5

This Phase IV randomised trial (PRISMA-ESCUDDO) is evaluating whether a single dose of HPV vaccine — either nonavalent (9-valent) or bivalent — is sufficient to protect young adult women (ages 18–30) against persistent HPV16/18 cervical infections in Costa Rica. Current WHO guidelines recommend two doses for adolescents aged 9–14 and three doses for those 15 and older; this trial directly challenges whether the multi-dose schedule is necessary for young adults. The primary endpoint is incident HPV16/18 cervical infection persisting six months or more, assessed in women who are HPV16/18 DNA-negative at baseline. The trial is currently active but not recruiting. No efficacy results are reported in this abstract; this registration record describes the study design and objectives only.

Key Findings

Breakthroughs & Major Findings

Section A is dominated by tebentafusp (IMCgp100), whose phase III OS benefit in HLA-A*02:01-positive advanced uveal melanoma stands as the week's single clearest clinical landmark. Uveal melanoma has long resisted checkpoint inhibition, partly because its low mutational burden limits neoantigen presentation; tebentafusp circumvents this by co-opting the HLA-peptide/TCR axis to redirect polyclonal T-cells against an intracellular antigen, gp100. Its approval validates the broader ImmTAC platform and raises immediate questions about whether brenetefusp and cutaneous melanoma applications will replicate this success. The remaining five papers in this section are all recruiting trials or protocol registrations with no results data — a notable imbalance in evidentiary weight. Among them, the liso-cel MRD-guided CAR T trial in LBCL (Paper 5) and the epcoritamab/R-miniCVP study for anthracycline-ineligible DLBCL (Paper 4) address high-priority unmet needs. The olverembatinib CML trial (Paper 2) and the pembrolizumab/sac-TMT squamous NSCLC maintenance study (Paper 3) represent rational next-generation hypotheses but offer no data yet. The diosmin/hesperidin nephroprotection trial (Paper 6) is the weakest entry — an incomplete abstract with no results that does not warrant 'breakthrough' classification.

PUBMED  ·  2026-12-01  ·  Significance: 5/5

This is a product review of tebentafusp (IMCgp100, Kimmtrak), a first-in-class Immune-mobilizing Monoclonal T-cell receptor Against Cancer (ImmTAC) biologic approved for HLA-A*02:01-positive advanced uveal melanoma. Tebentafusp is a fusion protein combining an affinity-enhanced soluble T-cell receptor (TCR) targeting the gp100(280-288)/HLA-A*02:01 complex with an anti-CD3 scFv, redirecting polyclonal T-cells to lyse melanoma cells. In the phase III IMCgp100-202 trial, tebentafusp demonstrated a significant overall survival (OS) benefit versus investigator's choice in the first-line setting. The safety profile features predictable on-target cytokine release syndrome and skin reactions, both attenuating over time. The review also discusses the broader ImmTAC platform and pipeline, including brenetefusp and exploration in cutaneous melanoma.

Key Findings

CLINICALTRIALS  ·  2025-02-10  ·  Significance: 3/5

This is a recruiting Phase II clinical trial (NCT06817720) led by MD Anderson Cancer Center evaluating olverembatinib — a third-generation BCR::ABL1 tyrosine kinase inhibitor (TKI) — as monotherapy in adults with newly diagnosed Philadelphia chromosome-positive or BCR::ABL1-positive chronic myeloid leukemia (CML) in chronic phase. The primary endpoint is the rate of major molecular response (MMR) by 12 months. Secondary endpoints include complete cytogenetic response (CCyR) by 12 months, deep molecular response rates (MR4.5) at multiple timepoints, sustained deep molecular response, event-free survival, overall survival, toxicity, and health-related quality of life. Participants with brief prior exposure (≤30 days) to hydroxyurea, cytarabine, or an FDA-approved TKI remain eligible. No efficacy results are yet available as the trial is actively recruiting.

Key Findings

CLINICALTRIALS  ·  2024-05-20  ·  Significance: 3/5

This is a recruiting Phase 3 randomised controlled trial (NCT06422143) evaluating a novel maintenance strategy in first-line metastatic squamous non-small cell lung cancer (NSCLC). All participants first receive four induction cycles of pembrolizumab plus carboplatin and paclitaxel or nab-paclitaxel. They are then randomised to maintenance pembrolizumab alone versus maintenance pembrolizumab combined with sacituzumab tirumotecan (sac-TMT; MK-2870), an antibody-drug conjugate. The primary hypothesis is that adding sac-TMT maintenance to pembrolizumab is superior with respect to overall survival (OS). Eligible patients must have histologically or cytologically confirmed Stage IV squamous NSCLC with measurable disease per RECIST 1.1. The trial is sponsored by Merck Sharp & Dohme LLC. As a recruiting trial, no efficacy or safety results are yet available from this abstract.

Key Findings

CLINICALTRIALS  ·  2023-09-21  ·  Significance: 3/5

A Phase 2 recruiting trial (NCT06045247) from MD Anderson Cancer Center investigating epcoritamab — a CD3×CD20 bispecific antibody — in combination with R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in a specific underserved population: older/unfit or frail patients, and those ineligible for anthracycline-based therapy (e.g., due to heart failure). The standard-of-care R-CHOP regimen is not tolerable for these patients due to doxorubicin's cardiotoxicity, leaving a significant treatment gap. This trial aims to assess whether adding epcoritamab to the reduced-intensity R-miniCVP backbone can improve complete response (CR) rates while maintaining an acceptable safety profile. Results are not yet available as the trial is actively recruiting.

Key Findings

CLINICALTRIALS  ·  2026-01-05  ·  Significance: 3/5

A Phase 2 trial (active, not yet recruiting) from MD Anderson Cancer Center investigating whether lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, can prevent disease recurrence in patients with large B-cell lymphoma (LBCL) who have achieved a complete response after standard first-line therapy but remain minimal residual disease (MRD)-positive as detected by the Foresight CLARITY™ assay. The study targets a high-risk subgroup — those with detectable circulating lymphoma DNA despite apparent clinical remission — and aims to determine whether early CAR T intervention in this setting can improve event-free survival. Primary and secondary endpoints include EFS, MRD conversion to undetectable, PFS, overall survival, and safety. Note: this is a trial registration record, not a results publication; no efficacy or outcome data are available.

Key Findings

CLINICALTRIALS  ·  2026-05-20  ·  Significance: 2/5

This is an active Phase 4 prospective randomized controlled trial (NCT07598214) being conducted at Beni-Suef University, enrolling approximately 100 cancer patients receiving platinum-based chemotherapy. The study evaluates whether the flavonoid combination diosmin/hesperidin can protect against cisplatin-induced nephrotoxicity. Patients are randomized into a control arm (standard platinum-based chemotherapy alone, n=37) and a test arm (standard chemotherapy plus diosmin/hesperidin, n=37). The abstract is incomplete — eligibility criteria and primary/secondary endpoints are truncated, and no results are available as the trial is currently recruiting (planned January–September 2025). No findings can be reported at this stage.

Key Findings

Diagnostic Advances

Diagnostic advances this week are anchored by the only paper in the section to report results: the biomarker trajectory study linking post-diagnosis glucose, albumin, and uric acid patterns to cardiovascular disease risk in cancer survivors (Paper 1). The finding that a high-and-rising glucose trajectory confers a 110% increase in CVD risk — and that even low-normal albumin trajectories are prognostically meaningful — has immediate relevance for cardio-oncology monitoring protocols. Latent class growth modelling of longitudinal biomarkers is a methodologically underutilised approach in survivorship research, and this study offers a template. The remaining five papers are trial registrations without results. The Knight SHIFT circadian immunotherapy scheduling trial (Paper 4) is conceptually provocative — if time-of-day administration modulates immunotherapy efficacy via circadian immune variation, it would represent a zero-cost, universally implementable optimisation — but the hypothesis remains untested. The encorafenib/cetuximab/nivolumab MSS BRAF V600E mCRC trial (Paper 3) and the DKN-01/pembrolizumab endometrial cancer study (Paper 6) both pursue biomarker-selected immunotherapy combinations in notoriously checkpoint-resistant contexts. Overall, this section would benefit from a broader search window to capture more results-bearing diagnostic papers.

PUBMED  ·  2026-05-25  ·  Significance: 3/5

This cohort study (1985–2020) examined post-diagnosis biomarker trajectories in cancer patients and their associations with subsequent cardiovascular disease (CVD) risk. Using latent class growth modelling on 11 biomarkers, the authors identified distinct longitudinal trajectory patterns, then applied Cox regression to assess CVD risk. Three biomarkers emerged as notably associated with CVD risk: glucose, albumin, and uric acid. The study addresses an important gap in cancer survivorship care — namely, how to stratify cancer patients for CVD risk — but is observational in nature and authors explicitly note that biological mechanisms remain to be elucidated and associations require validation. No specific cancer type was restricted; the study population appears to span multiple cancer diagnoses. Results represent associations, not causal relationships.

Key Findings

CLINICALTRIALS  ·  2025-01-30  ·  Significance: 3/5

This is a global, multicenter, randomized, open-label Phase 3 clinical trial (NCT06801834) sponsored by Gilead Sciences, currently recruiting. The study compares sacituzumab govitecan (SG; Trodelvy®), a Trop-2-directed antibody-drug conjugate, against standard of care (SOC) in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). The primary endpoint is overall survival (OS). Eligible participants must have histologically confirmed SCLC, an ECOG performance status of 0 or 1, and measurable disease per RECIST v1.1 criteria. As this is an active recruiting trial with no results reported yet, no efficacy or safety findings are available from this abstract. The trial represents a significant attempt to address the high unmet need in relapsed/refractory ES-SCLC, a setting with limited effective therapeutic options.

Key Findings

CLINICALTRIALS  ·  2019-07-12  ·  Significance: 3/5

This is an active Phase I/II clinical trial (NCT04017650) conducted at MD Anderson Cancer Center evaluating the combination of encorafenib (BRAF inhibitor), cetuximab (EGFR inhibitor), and nivolumab (PD-1 checkpoint inhibitor) in patients with microsatellite stable (MSS), BRAF V600E-mutated metastatic or unresectable colorectal cancer. The trial addresses a high-unmet-need population: MSS BRAF V600E-mutated mCRC is notoriously resistant to immunotherapy alone. The Phase I component establishes safety and optimal dosing; the Phase II component evaluates efficacy. Primary endpoints are overall response rate (ORR) and safety/tolerability. Secondary endpoints include progression-free survival (PFS), overall survival (OS), and time to response (TTR). No results are reported in this abstract; this is a trial registration record.

Key Findings

CLINICALTRIALS  ·  2026-02-12  ·  Significance: 3/5

This phase IV prospective, multi-histology pragmatic trial (Knight SHIFT) from the OHSU Knight Cancer Institute is evaluating whether the time of day (ToD) of standard-of-care immunotherapy administration — morning (before 11:00 am) versus afternoon (12:00 pm or later) — affects clinical outcomes in patients with advanced or metastatic solid tumors. The biological rationale is grounded in circadian rhythm biology: immune cell activity varies across the day, and the researchers hypothesize this may modulate immunotherapy response. The trial is currently recruiting and is not testing a novel agent, but rather a pragmatic scheduling variable. Primary endpoint is progression-free survival; secondary endpoints include overall survival and rates of immune-related adverse events (irAEs). No results are available at this time — this is a trial registration record.

Key Findings

CLINICALTRIALS  ·  2018-10-18  ·  Significance: 3/5

This is an active Phase II single-arm trial (NCT03710772) conducted at MD Anderson Cancer Center evaluating a novel combination regimen in newly diagnosed, young mantle cell lymphoma (MCL) patients. The regimen consists of ibrutinib (BTK inhibitor) plus rituximab (anti-CD20 monoclonal antibody) as an initial window, followed by venetoclax (Bcl-2 inhibitor) and hyper-CVAD consolidation chemotherapy (cyclophosphamide, vincristine, doxorubicin, dexamethasone). The primary endpoint is complete response (CR) rate. Secondary endpoints include safety profile, progression-free survival (PFS), and overall survival (OS). The abstract describes the trial design and rationale; no results data are yet reported in this registration record. Evidence is therefore limited to trial design at this stage.

Key Findings

CLINICALTRIALS  ·  2023-03-09  ·  Significance: 3/5

This is an active Phase 2 clinical trial (NCT05761951) conducted at MD Anderson Cancer Center evaluating the combination of DKN-01 (a DKK1 inhibitor targeting the Wnt/β-catenin pathway) and pembrolizumab (a PD-1 checkpoint inhibitor) in women with advanced or recurrent endometrial cancer. The trial targets two populations: endometrioid endometrial cancer and non-endometrioid endometrial cancer harbouring Wnt/β-catenin activating mutations. The primary endpoint is objective response rate (ORR). Secondary endpoints include clinical benefit rate, progression-free survival, overall survival, and duration of response. The study is currently active but not recruiting. No efficacy or safety results are reported in this registry entry; this summary reflects trial design only.

Key Findings

Novel Treatments & Therapies

The dMMR/MSI-H colorectal cancer meta-analysis (Paper 1) is this section's most actionable paper, synthesising six RCTs (n=1,460) to clarify the response-toxicity trade-off between PD-1 monotherapy and nivolumab/ipilimumab dual immunotherapy. The critical finding — that OS hazard ratios across all four reporting trials cross 1.0 — should temper enthusiasm for routine dual checkpoint escalation, even as dual therapy demonstrates higher ORR. This stands in instructive contrast to the iparomlimab/tolvorlimab dual checkpoint neoadjuvant trial in dMMR/MSI-H gastric cancer (Paper 4), which cites 60% pCR with tremelimumab/durvalumab in small cohorts as justification for its bifunctional antibody approach. Readers should note the tension: population-level OS benefit from dual checkpoint remains unproven even in the most immunotherapy-sensitive CRC subtype. The NRG-GY037 cervical cancer induction immunotherapy trial (Paper 2) and the brentuximab vedotin/nivolumab Hodgkin lymphoma response-adapted study (Paper 3) both test the hypothesis that intensifying upfront immunotherapy improves on an already improving standard of care. The glofitamab/obinutuzumab post-CAR T MCL trial (Paper 5) and the iadademstat ES-SCLC maintenance study (Paper 6) address critical post-progression gaps where few options currently exist.

PUBMED  ·  2026-05-21  ·  Significance: 3/5

This meta-analysis synthesises data from six randomised controlled trials (n=1,460 patients) to compare PD-1/PD-L1 monotherapy, dual immunotherapy (nivolumab plus ipilimumab), and chemotherapy in dMMR/MSI-H metastatic colorectal cancer. PD-1/PD-L1 monotherapy significantly improved objective response rate versus chemotherapy and demonstrated a markedly lower rate of grade ≥3 adverse events. Dual immunotherapy showed a significantly higher ORR than monotherapy, but with significantly increased toxicity. Crucially, OS hazard ratios across all four studies reporting survival crossed 1.0, and PFS benefit was inconsistent across trials. The authors conclude that personalised risk-benefit assessment is warranted, with future work needed on biomarker-driven patient selection.

Key Findings

CLINICALTRIALS  ·  2025-07-14  ·  Significance: 4/5

This is an active Phase III randomised controlled trial (NRG-GY037) investigating whether adding induction immunotherapy and chemotherapy (carboplatin + paclitaxel + pembrolizumab) prior to standard concurrent chemoradiation therapy (cisplatin + radiation) plus pembrolizumab improves outcomes in patients with high-risk locally advanced cervical cancer (T3/T4 disease with or without lymph node involvement). The control arm receives concurrent chemoradiation with pembrolizumab followed by pembrolizumab maintenance. The experimental arm adds an induction phase of carboplatin, paclitaxel, and pembrolizumab before proceeding to the same chemoradiation-based regimen. The primary endpoint is progression-free survival (PFS), with overall survival (OS) and toxicity as key secondary endpoints. The trial is currently recruiting and is sponsored by the National Cancer Institute (NCI).

Key Findings

CLINICALTRIALS  ·  2023-01-09  ·  Significance: 4/5

This is an active Phase 3 randomized clinical trial (NCT05675410) sponsored by the NCI, enrolling patients aged 5–60 years with newly diagnosed Stage I and II classical Hodgkin lymphoma (cHL). The trial uses a response-adapted design: after 2 cycles of standard ABVD chemotherapy, patients are stratified by early response on PET scan (PET2). The primary comparison tests whether adding immunotherapy — specifically the antibody-drug conjugate brentuximab vedotin (anti-CD30) plus the PD-1 checkpoint inhibitor nivolumab — to standard chemotherapy (with or without radiation therapy) improves progression-free survival (PFS) compared to standard treatment alone. The trial covers both rapid early responders and non-rapid early responders as separate primary objectives. Results are not yet available as the trial is currently recruiting.

Key Findings

CLINICALTRIALS  ·  2026-05-19  ·  Significance: 3/5

This is a prospective, single-arm, single-center Phase II clinical trial (not yet recruiting) evaluating iparomlimab/tolvorlimab (QL1706) — a bifunctional anti-PD-1/anti-CTLA-4 combination antibody — as neoadjuvant immunotherapy in patients with locally advanced, dMMR/MSI-H gastric adenocarcinoma. The rationale is grounded in the known chemotherapy resistance and immunotherapy sensitivity of the dMMR/MSI-H subtype, with prior single-agent PD-1 inhibitor studies showing pCR rates of ~32–34% and dual checkpoint blockade (tremelimumab + durvalumab) achieving up to 60% pCR in small cohorts. QL1706 uses MabPair® technology to co-administer PD-1 and CTLA-4 blockade in a fixed 2:1 ratio via a single infusion. The primary endpoint is pathological complete response rate; secondary endpoints include ORR, MPR, R0 resection rate, PFS, OS, and safety. This is a registration record only — no efficacy or safety results are available.

Key Findings

CLINICALTRIALS  ·  2025-06-04  ·  Significance: 3/5

This Phase II trial (NCT07003295), currently recruiting, is evaluating the combination of glofitamab (a CD3×CD20 bispecific antibody) and obinutuzumab (an anti-CD20 monoclonal antibody) in patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received CD19-directed CAR T-cell therapy — a population with very limited treatment options. The primary endpoint is objective response rate (ORR). Secondary endpoints include complete response (CR) rate, progression-free survival (PFS) and overall survival (OS) at 24 months, and incidence of grade 3–4 cytokine release syndrome (CRS). The study targets a clinically relevant and underserved niche: post-CAR T MCL relapse, where CD19 antigen loss may make CD20-directed bispecific approaches mechanistically rational. Results are pending as the trial is actively recruiting.

Key Findings

CLINICALTRIALS  ·  2024-03-01  ·  Significance: 3/5

This is a phase I/II clinical trial (NCT06287775) currently recruiting, sponsored by the National Cancer Institute. The study investigates iadademstat — an enzyme inhibitor targeting cell growth pathways — combined with immune checkpoint inhibitors (atezolizumab or durvalumab) as maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) who have completed 4–6 cycles of standard platinum-etoposide chemoimmunotherapy. The phase I component establishes the safe dose of iadademstat; the phase II randomized component compares progression-free survival between iadademstat plus ICI versus ICI maintenance alone. Secondary endpoints include overall survival and objective response rate. An exploratory aim will assess ctDNA minimal residual disease as a biomarker. Results are not yet available, as the trial is actively recruiting.

Key Findings

Clinical Trials

This week's clinical trials section reflects oncology's ongoing effort to refine treatment sequencing and expand access to proven regimens. The ALBORAN study (Paper 2) is the most immediately practice-relevant entry: it extends the phase III ADRIATIC durvalumab consolidation data into a real-world LS-SCLC population, crucially including sequential CRT recipients and ECOG PS 2 patients excluded from the pivotal trial — groups that represent a meaningful proportion of clinical practice. This real-world expansion mirrors a broader trend visible across sections, where post-approval studies are filling the gaps left by strict RCT eligibility. The TRTRM/ACTTOP geriatric oncology trial (Paper 3) is methodologically important: if a locally validated Chinese-population toxicity prediction model outperforms CARG and CRASH in a prospective RCT, it could catalyse region-specific tool development globally. The INSIGNA biomarker-driven NSCLC sequencing trial (Paper 6) and the gastric/esophageal PARAMUNE checkpoint escalation study (Paper 4) both address sequencing questions that remain unresolved despite multiple prior trials. The mFOLFOXIRI bevacizumab mCRC trial (Paper 1) and the pyrotinib real-world HER2+ breast cancer study (Paper 5) are important for Asian patient populations historically underrepresented in landmark trials. No results are available from any of the six papers in this section.

CLINICALTRIALS  ·  2020-01-18  ·  Significance: 3/5

A randomised, open-label, Phase 3 multicentre trial evaluating a modified triplet chemotherapy regimen (mFOLFOXIRI) plus bevacizumab versus mFOLFOX-6 plus bevacizumab as first-line treatment in Chinese patients with unresectable metastatic colorectal cancer (mCRC). The study is motivated by the observation that standard European/American triplet regimens carry disproportionately high toxicity in Asian populations, and that robust efficacy data for Chinese patients are lacking. Primary and secondary endpoints include PFS, ORR, OS, DCR, surgical resection rate, safety, and health-related quality of life. The trial is currently active but not recruiting. Note: this record is a trial registration; no efficacy or safety results are reported in the available abstract.

Key Findings

CLINICALTRIALS  ·  2025-05-28  ·  Significance: 3/5

A Phase IIIb, single-arm, real-world study (ALBORAN) recruiting in Spain to assess the safety and effectiveness of durvalumab as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not progressed after either concurrent or sequential platinum-based chemoradiotherapy. This study is sponsored by AstraZeneca and builds on the pivotal Phase III ADRIATIC trial, which demonstrated statistically significant and clinically meaningful improvements in both overall survival (OS) and progression-free survival (PFS) with durvalumab consolidation versus placebo after concurrent CRT. ALBORAN expands the eligible population to include patients who received sequential CRT and those with ECOG PS 2 post-CRT — groups excluded from ADRIATIC — to generate real-world evidence informing clinical practice in Spain.

Key Findings

CLINICALTRIALS  ·  2026-03-20  ·  Significance: 3/5

This is a multi-centre, open-label, randomised controlled trial (RCT) currently recruiting in Hong Kong, evaluating the clinical utility of the Treatment-Related Toxicity Risk Model (TRTRM/ACTTOP) in older cancer patients. The TRTRM was developed and validated in a Hong Kong cohort of 700 older patients and is designed to predict severe treatment-related toxicities across chemotherapy, targeted therapy, and immunotherapy — modalities not fully covered by existing tools such as CARG and CRASH. Patients aged 65 or older starting a new systemic anti-cancer treatment are randomised 1:1 to TRTRM-guided care (with a "start-low, go-slow" dosing strategy for intermediate/high-risk patients) versus usual care. The primary outcome is incidence of grade 3+ toxicities within two months of treatment initiation. The trial addresses an important gap in geriatric oncology tooling for Chinese and Asian populations.

Key Findings

CLINICALTRIALS  ·  2024-01-12  ·  Significance: 3/5

This is an actively recruiting Phase II/III randomized controlled trial (PARAMUNE, NCT06203600) sponsored by the National Cancer Institute. It investigates whether adding nivolumab (a PD-1 checkpoint inhibitor) to the standard second-line regimen of paclitaxel plus ramucirumab improves outcomes in patients with advanced or locally unresectable gastric, gastroesophageal junction, or esophageal adenocarcinoma expressing PD-L1 with a Combined Positive Score (CPS) ≥ 1. The trial uses a seamless Phase II/III design: Phase II assesses whether progression-free survival (PFS) improvement is sufficient to advance to Phase III, which will then evaluate overall survival (OS) as the primary endpoint. Results are not yet available, as the trial is currently recruiting.

Key Findings

CLINICALTRIALS  ·  2026-05-20  ·  Significance: 3/5

This is a multicenter, prospective Phase 4 real-world study (not yet recruiting) planned at Peking University People's Hospital, targeting 500 patients with HER2-positive advanced breast cancer receiving first- or second-line treatment. The study evaluates the efficacy and safety of pyrotinib-based regimens (first-line: pyrotinib plus trastuzumab and chemotherapy; second-line: pyrotinib plus capecitabine) followed sequentially by the antibody-drug conjugate (ADC) disitamab vedotin upon disease progression or intolerance. The primary endpoint is real-world second progression-free survival (rwPFS2). While pyrotinib has demonstrated efficacy in Phase III trials, this study addresses a gap in real-world evidence regarding the sequential use of pyrotinib-containing regimens followed by disitamab vedotin. Note: the abstract contains a possible transcription inconsistency, referring to "recindopril trastuzumab" in the closing sentence, which likely refers to disitamab vedotin.

Key Findings

CLINICALTRIALS  ·  2019-01-04  ·  Significance: 3/5

This is an active Phase III randomized clinical trial (EA5163/S1709, INSIGNA) evaluating treatment sequencing strategies for first-line immunotherapy with or without chemotherapy in advanced non-squamous NSCLC. The trial compares two experimental arms against a control arm: Arm A (pembrolizumab monotherapy induction followed by pemetrexed/carboplatin ± pembrolizumab at progression), Arm B (a variant of sequential therapy), and Arm C (standard induction with pembrolizumab + pemetrexed/carboplatin followed by pembrolizumab + pemetrexed maintenance). The primary endpoint is overall survival (OS) for each experimental arm versus control. The trial is biomarker-driven, incorporating immunobiomarker signature analysis to guide patient selection and analysis. As a trial registration record rather than a results publication, no efficacy or safety outcome data are reported in this abstract.

Key Findings